To include your compound in the COVID-19 Resource Center, submit it here.

Stoke unveils Dravet data that supported $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) presented the preclinical data for its Dravet syndrome antisense oligonucleotide (ASO) therapy that CEO Ed Kaye said helped it raise its $90 million series B round in October.

In a mouse model of Dravet syndrome, 99%

Read the full 400 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE